CannTrust Holdings Inc. Announces $75 Million Bought Deal Financing

CannTrust Holdings Inc. (TSX:TRST), a licensed producer of medical cannabis under the Health Canada Access to Cannabis for Medical Purposes Regulation program, today announced that it has entered into an agreement with a syndicate of underwriters led by Canaccord Genuity Corp. and GMP Securities L.P., pursuant to which the Underwriters will purchase, on a bought deal basis pursuant to the filing of a short form prospectus, an aggregate of 8,350,000 units of the Company at a price of $9.00per Unit for aggregate gross proceeds of $75,150,000.

Canopy Rivers Announces "Micro Cannabis, Macro Impact" Pitch Day For Cannabis Entrepreneurs

Canopy Rivers Corporation is excited to help foster growth in the Canadian cannabis landscape by hosting a pitch day for cannabis entrepreneurs ahead of impending adult use legalization. In accordance with the proposed regulations underneath the Cannabis Act (Bill C-45) and the new "micro" class of licenses, the Company is offering up to $1,000,000 of seed capital to support a diverse range of aspiring cannabis entrepreneurs.

CanopyVentures Makes First Growth Round Investment, Invests $750,000 in BDS Analytics

CanopyVentures™, a venture capital firm investing in companies providing value throughout the legal cannabis supply chain, today announced an investment of $750,000 in BDS Analytics, the cannabis industry's leader in comprehensive, actionable, and accurate market intelligence and consumer research. The Series B funding for BDS Analytics marks Canopy's first investment through Canopy Ventures I, the firm's $50 million venture fund targeting growth stage companies.

Aurora Cannabis to Acquire MedReleaf

Aurora Cannabis Inc.(TSX: ACB) and MedReleaf Corp. (TSX: LEAF) are pleased to announce that they have entered into a definitive arrangement agreement whereby Aurora intends to acquire all of the issued and outstanding common shares of MedReleaf in an all-share transaction valued at approximately C$3.2 billion on a fully diluted basis.

InMed Files Patent Application for INM-085 Glaucoma Program

InMed Pharmaceuticals Inc. (TSX:IN; OTCQX:IMLFF), today announced it has filed a Patent Cooperation Treaty application for INM-085 as a cannabinoid-based topical therapy for glaucoma, which includes protection of its technology in about 150 different countries including the United States, and claims a priority date from May 8, 2018 (PCT/CA2018/050548).

InMed Reports Third Quarter Fiscal 2018 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today reported financial results for the three and nine months ended March 31, 2018, which is the Company's third quarter of fiscal year 2018 ("3Q18").